Homepage Top Section2

The in-human study follows positive pre-clinical results for the treatment candidate, as well as successive approval of the investigational new drug application by the Korean Ministry of Food

Tremfya is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin (IL)-23 and prevents its interaction with the IL-23 receptor, as per Janssen.

The deal gives Roche exclusive rights for the co-development and commercialisation of pralsetinib outside the US with the exclusion of Mainland China, Hong Kong, Macau, and Taiwan. In

The EC approval allows using Lynparza as a maintenance treatment for adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed

The trial of EIDD-2801 will be held using a newly launched Covid-19 drug testing platform called AGILE, which has been developed in the UK by the University of

The primary endpoint of the SEP380-201 trial was the variation from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score after six weeks of treatment with SEP-4199. According

APG-115 has been designed by Ascentage Pharma as an orally administered, selective, small-molecule inhibitor of the MDM2-p53 PPI. KEYTRUDA, on the other hand, is an anti-PD-1 therapy, which

Rukobia is a novel attachment inhibitor, which is designed to treat HIV-1 infection, is specified for use in combination with other antiretroviral (ARV) therapies in heavily treatment-experienced (HTE)

As a result of the approval, Janssen is currently collaborating with the World Health Organisation (WHO) on vaccine pre-qualification to advance the registration of its preventive Ebola vaccine